Ascentage Pharma director amends holdings

Ascentage Pharma Group International director David Sidransky filed an amended Form 3 to correct his reported equity holdings.

Accepted by SEC EDGAR 03/23/2026 - 07:14 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascentage Pharma Group International director David Sidransky filed an amended Form 3 to correct his reported equity holdings. The filing now shows stock options over 18,850 Ordinary Shares at an exercise price of 8.1400 expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025. It also reflects 28,850 restricted share units that vest in four equal annual increments on November 26 of 2026, 2027, 2028 and 2029, plus 10,641 directly held Ordinary Shares. Footnotes state that prior submissions inadvertently misstated the number of Ordinary Shares and option details.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider SIDRANSKY DAVID

Role Director

Type	Security	Shares	Price	Value
Holding	Options	--	--	--
Holding	Restricted share units	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Options — 18,850 contracts (Direct); Restricted share units — 28,850 contracts (Direct); Ordinary Shares — 10,641 shares (Direct)

Footnotes (5)

1. F1. The number of Ordinary Shares were inadvertently not reported in the original submission.
2. F2. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.
3. F3. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
4. F4. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
5. F5. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascentage Pharma (AAPG) director David Sidransky report in this Form 3/A?

David Sidransky reported corrected equity holdings in Ascentage Pharma, including options, restricted share units, and Ordinary Shares. The amendment updates previously misstated numbers and clarifies vesting schedules and terms for his compensation-related awards and direct share ownership.

How many stock options does David Sidransky hold in Ascentage Pharma (AAPG)?

The filing shows options over 18,850 Ascentage Pharma Ordinary Shares at an exercise price of 8.1400. These options vest in twelve equal tranches on the 26th of each month starting November 26, 2025, and expire on November 26, 2035.

What restricted share units did David Sidransky disclose for Ascentage Pharma (AAPG)?

Sidransky reported 28,850 restricted share units, each representing one Ordinary Share upon vesting. The RSUs vest in four equal increments on November 26 of 2026, 2027, 2028 and 2029, providing a multi-year, time-based equity compensation structure tied to continued service.

How many Ascentage Pharma (AAPG) Ordinary Shares does David Sidransky directly own?

The amended Form 3 states that Sidransky directly holds 10,641 Ordinary Shares of Ascentage Pharma after the reported holdings. This figure reflects a correction, as the number of Ordinary Shares was inadvertently not reported in the original submission, according to the footnotes.

Why was this Ascentage Pharma (AAPG) Form 3/A amendment necessary?

The amendment was filed because earlier disclosures contained errors. Footnotes explain that the number of Ordinary Shares was inadvertently omitted and the number of share options and/or vesting was incorrectly reported in the original submission, requiring this corrected holdings statement.

What do the footnotes say about Ascentage Pharma (AAPG) option and RSU terms?

Footnotes explain the options vest in twelve equal tranches starting November 26, 2025, with the exercise price set in HKD and converted to USD. They also state each RSU converts into one Ordinary Share and vests annually from 2026 through 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SIDRANSKY DAVID

(Last) (First) (Middle)

700 KING FARM BLVD

STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	10,641	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(2)	11/26/2035	Ordinary Shares	18,850(5)	$8.14(3)	D
Restricted share units	(4)	(4)	Ordinary Shares	28,850(5)	$0	D

Explanation of Responses:

1. The number of Ordinary Shares were inadvertently not reported in the original submission.

2. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

3. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

4. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

5. The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

Remarks:

	/David Sidransky/	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)